Registry of long-term antithrombotic therapy for coronary artery disease
Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes
This study looks at how safe and effective long-term blood-thinning treatments are for people with coronary artery disease, including those who have had heart attacks or heart surgeries.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Government |
| Locations | 1 site (Moscow) |
| Trial ID | NCT04347200 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the rates of ischemic and hemorrhagic complications associated with long-term antithrombotic therapy in patients suffering from chronic coronary syndromes. Conducted at a single center in Russia, it focuses on individuals with confirmed coronary artery disease, including those with a history of myocardial infarction or revascularization. The study will collect data on the effectiveness and safety of antiplatelet drugs over an extended period.
Who should consider this trial
Good fit: Ideal candidates are patients with confirmed coronary artery disease who require long-term antithrombotic therapy.
Not a fit: Patients with acute coronary syndrome within the past 12 months or severe comorbid conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management and safety of antithrombotic therapy in patients with coronary artery disease.
How similar studies have performed: Other studies have shown varying degrees of success with long-term antithrombotic therapy in similar patient populations, but this specific registry approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * coronary artery disease , confirmed by history of myocardial infarction, or revascularization, or definitive evidence of CAD on imaging Exclusion Criteria: * Subjects who are unwilling or unable to provide informed consent. * Acute coronary syndrome within 12 months before inclusion * Severe chronic heart failure (NYHA IV) * Stroke within 6 months before inclusion * Severe liver or muscle disease * Severe kidney disease / renal failure with creatinine \> 3 mg/dl * Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention -
Where this trial is running
Moscow
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation — Moscow, Russia (Recruiting)
Study contacts
- Principal investigator: Elizaveta Panchenko, PhD — National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Study coordinator: Andrey Komarov, PhD
- Email: andrkomarov@mail.ru
- Phone: +79161813257
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.